Back to search
FDAFDA · Food and drugs·Recall number D-0018-2023

Pyridostigmine Bromide Oral Solution, USP 60 mg/5 mL Delivers 5 mL, packaged in 5mL unit-dose cup, Rx only, Dist. by: VistaPharm, NDC 66689-406-01

Published November 2, 2022 · Recall initiated: September 30, 2022

Summary

FDA records drug Class II recall D-0018-2023, published November 2, 2022 and initiated September 30, 2022. Recalling firm: VistaPharm, Inc.; Status: Terminated; Reported quantity: 1980 cups; Lot: Lot#: 832400, Exp 08/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations: Out of specification for assay of one of the preservative ingredients.

What to do

Voluntary: Firm initiated · Letter

Get an email if PYRIDOSTIGMINE BROMIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
PYRIDOSTIGMINE BROMIDE
Manufacturer
VistaPharm, Inc.
Distributor
USA Nationwide
Lot
Lot#: 832400, Exp 08/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Pyridostigmine Bromide Oral Solution, USP 60 mg/5 mL Delivers 5 mL, packaged in 5mL unit-dose cup, Rx only, Dist. by: VistaPharm, NDC 66689-406-01 recalled?

Yes. FDA published recall D-0018-2023 on November 2, 2022. Reported hazard: cGMP Deviations: Out of specification for assay of one of the preservative ingredients.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: PYRIDOSTIGMINE BROMIDE.